Published in Lab Business Week, February 25th, 2007
The firm has commenced operations to pursue and fund collaborative ventures to develop specialty pharmaceutical solid dose forms, and in-license late stage drug products. Brian T. Labs will market the products in the United States and, with its partners, in the rest of the world.
"We are also searching for equity investment in, or to acquire, a small ongoing company which can be used as a platform to manage our new product development programs,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.